About Us
 Who We Are

Altor BioScience Corporation is a biopharmaceutical company engaged in the discovery, development and commercialization of high-value, targeted immunotherapeutic agents for the treatment of cancer, viral infections, and autoimmune diseases.

Our Focus

Altor has two products in clinical-stage and several others in research and preclinical development. Its lead product, STAR™ -Ck or ALT-801, an anti-cancer drug, has begun a Phase I clinical trial. The Company’s second clinical-stage product, a monoclonal antibody which prevents and treats staphylococcal infections in premature neonates, has been licensed to Biosynexus/GlaxoSmithKline. This product has completed Phase IIa clinical trials and is expected to soon begin later-stage trials. (more on the clinical trial...). Management believes the total U.S. market opportunity for all of Altor’s products and indications exceeds $13 billion.

Overview and History

Altor was formed in 2002 by Hing C. Wong, Ph.D., as a spin-off from Sunol Molecular Corporation (“Sunol”), and is backed by leading venture capital funds, including Sanderling Ventures and TVM Capital. The Company’s proprietary technology, referred to as its STAR™ platform, has been in development for over ten years. Dr. Wong and Peter Rhode, Ph.D., Vice President of Research and Development, began developing the STAR™ platform while at Baxter Healthcare and continued its development at Sunol. Altor’s STAR™ technology is founded on a unique platform of proprietary technologies and skills that facilitate the rapid manipulation and development of soluble T-cell receptors (“TCR”) and major histocompatibility complex molecules (“MHC”). Altor employs this platform to improve the safety and efficacy of existing therapeutic drugs. The Company believes that its clinical development strategy of evaluating these drugs in their approved indications will minimize risk and facilitate rapid progress in clinical trials. The Company has secured its position with both a strong intellectual property portfolio and a pipeline of promising drug candidates. Altor is managed by a team with extensive experience and discipline in corporate finance, research and discovery, and product development, as well as regulatory and clinical affairs.

Altor Evolution and Major Milestones

Management, Scientific Staff & Boards...

Facility

Altor’s operations are located in facilities totaling 27,500 square feet in the Miami/Ft. Lauderdale area of South Florida. These facilities contain fully equipped laboratories built and outfitted specifically for biopharmaceutical research and development activities.

Back

© Altor BioScience Corporation, 2007